首页|不同类型SGLT2抑制剂对心力衰竭合并2型糖尿病患者临床预后的影响观察

不同类型SGLT2抑制剂对心力衰竭合并2型糖尿病患者临床预后的影响观察

Effect of Different Types of SGLT2 Inhibitors on Clinical Prognosis of Pa-tients with Heart Failure Complicated with Type 2 Diabetes Mellitus

扫码查看
目的 观察不同类型钠-葡萄糖协同转运蛋白2(Sodium-dependent Glucose Transporters 2,SGLT2)抑制剂在心力衰竭合并2型糖尿病患者中的治疗效果及对其临床预后的影响.方法 选取2022年10月—2023年10月揭西县人民医院内二科收治的250例心力衰竭合并2型糖尿病患者作为研究对象,依据患者SGLT2抑制剂使用情况分为5组,即卡格列净组、达格列净组、恩格列净组、艾托格列净组和对照组(仅接受常规治疗,不使用SGLT2抑制剂),每组50例.对比5组用药前后糖化血红蛋白(Glycosylated Hemoglobin A1c,HbA1c)、空腹血糖、餐后2 h血糖变化的情况以及治疗前后左室射血分数(Left Ventricular Ejection Fraction,LVEF)、脑钠肽(Brain Natriuretic Peptide,BNP)水平.结果 用药前,5组患者HbA1c、空腹血糖、餐后2 h血糖水平对比,差异无统计学意义(P均>0.05);用药2个月后,各组HbA1c、空腹血糖、餐后2 h血糖较治疗前均明显降低,且达格列净组的HbA1c水平低于其他各组,差异有统计学意义(P均<0.05).用药前,5组LVEF、BNP水平对比,差异无统计学意义(P>0.05);随访1年后,5组LVEF较治疗前明显上升,BNP较治疗前明显下降,且达格列净组LVEF高于其他各组,BNP低于其他各组,差异有统计学意义(P均<0.05).结论 不同类型SGLT2抑制剂在面对心力衰竭合并2型糖尿病患者时均能起到较理想的治疗效果,其中达格列净疗效略优于卡格列净、恩格列净、艾托格列净.
Objective To observe the therapeutic effect of different types of sodium-dependent glucose transporters 2(SGLT2)inhibitors in patients with heart failure and type 2 diabetes and their influence on clinical prognosis.Methods 250 patients with heart failure combined with type 2 diabetes mellitus admitted to the Department of Inter-nal Medicine Section Two of Jiexi County People's Hospital from October 2022 to October 2023 were selected as the study objects.According to the use of SGLT2 inhibitors,the patients were divided into 5 groups:cagliaglitzin group,dagliaglitzin group,engliaglitzin group and etoglitzin group and control group(only received conventional treatment without SGLT2 inhibitor),with 50 cases in each group.The changes of glycosylated hemoglobin(HbA1c),fasting blood glucose,2 h postprandial blood glucose,left ventricular ejection fraction(LVEF)and brain natriuretic peptide(BNP)before and after treatment were compared in the 5 groups.Results There was no statistically significant differ-ence in HbA1c,fasting blood glucose,2 h postprandial blood glucose levels among the 5 groups before treatment(all P>0.05).After 2 months of treatment,HbA1c,fasting blood glucose,2 h postprandial blood glucose levels in all groups was significantly lower than those before treatment,and the HbA1c level in dagliaglitzin group was lower than that in other groups,the differences were statistically significant(all P<0.05).There were no statistically significant differences in LVEF and BNP levels among the 5 groups before treatment(both P>0.05).After 1 year of follow-up,LVEF in the 5 groups was significantly higher than before treatment,BNP was significantly lower than before treat-ment,LVEF in dagliaglitzin group was higher than that in other groups,and BNP was lower than that in other groups,the differences were statistically significant(all P<0.05).Conclusion Different types of SGLT2 inhibitors can play an ideal therapeutic effect in the face of heart failure patients with type 2 diabetes.Among them,the efficacy of daglia-glitzin is slightly better than that of cagliaglitzin,cagliaglitzin,and etoglitzin.

Sodium-dependent glucose transporters 2Heart failureType 2 diabetes

张燕妮、庄明浩、陈山林、蔡芳芳

展开 >

广东省揭阳市揭西县人民医院内二科,广东揭阳 515400

钠-葡萄糖协同转运蛋白2抑制剂 心力衰竭 2型糖尿病

广东省揭阳市卫生健康局医学科学技术研究立项

揭市卫[2023]42号

2024

糖尿病新世界
中国病理生理学会

糖尿病新世界

影响因子:0.461
ISSN:1672-4062
年,卷(期):2024.27(4)
  • 11